FDA Advisory Panel Reviews Moderna's mRNA-Based Influenza Vaccine mFlusiva, a First-of-Its-Kind Shot for Adults 50 and Older
核心洞察
Moderna is seeking FDA approval for mFlusiva (搜索), the first mRNA-based influenza (搜索) vaccine, targeting adults aged 50 and older ahead of the winter flu season.
In a pivotal study of 40,000 participants aged 50 and older, the mRNA vaccine reduced flu cases by approximately 27% compared to a routinely used standard-dose vaccine, with no safety concerns reported by the FDA.
The application follows an unusual public dispute in which a former top FDA official blocked the filing, arguing the vaccine should have been compared against a high-dose senior formulation rather than a standard-dose brand.
U.S. health advisers convened Thursday to debate a new kind of influenza (搜索) vaccine — the first ever made with the same mRNA technology that proved pivotal in ending the COVID-19 (搜索) pandemic. Moderna is seeking Food and Drug Administration approval of its novel shot, dubbed mFlusiva (搜索), as an option for people aged 50 and older, with the FDA advisory committee meeting representing a critical step toward a final regulatory decision ahead of the coming winter flu season.
Tens of thousands of Americans die from influenza (搜索) every year, and older adults remain among the most vulnerable populations. While multiple types of flu vaccines are already available in the United States — including three formulations specifically recommended for people 65 and older — vaccines manufactured using the Nobel Prize-winning mRNA platform offer a distinct advantage: speed. Experts note that mRNA vaccines can be manufactured faster than conventional types, a capability that could prove essential if the shape-shifting influenza virus mutates in a manner requiring the rapid production of newly matched doses.
Clinical Evidence and Efficacy Data
In a large-scale study enrolling 40,000 people aged 50 and older, Moderna's mRNA influenza (搜索) vaccine reduced flu cases by approximately 27% compared to participants who received another routinely used vaccine brand. Ahead of the advisory committee meeting, the FDA published a favorable review of those data and reported no safety concerns associated with the investigational shot.
Moderna is pursuing full approval for mFlusiva (搜索) in the 50- to 64-year-old population, while simultaneously seeking authorization for use in those 65 and older as it conducts additional testing in that age group. The expert panel is also assessing results from a separate, smaller study that compared the mRNA shot directly with a high-dose influenza (搜索) vaccine recommended for seniors. That study found Moderna's shot generated flu-fighting antibodies similarly to the high-dose comparator.
Regulatory Controversy and Path Forward
Earlier this year, Moderna's data became the focus of a highly unusual public dispute when a then-top FDA official blocked the company's application for the first-of-its-kind shot. Dr. Vinay Prasad, the embattled vaccine chief at the time, argued that the company should have compared its vaccine to a high-dose flu vaccine recommended for seniors rather than a standard-dose brand. The episode was viewed as a sign of heightened vaccine scrutiny at the FDA under Health Secretary Robert F. Kennedy Jr.
Moderna challenged that decision, pointing out that FDA staff had previously approved the main study's design and citing the separate, smaller study comparing the mRNA shot with a high-dose senior vaccine. Days after the public spat, the FDA accepted Moderna's application, setting the stage for the current advisory committee review.
Outstanding Questions
Despite the favorable preliminary review, the FDA's initial assessment noted that the new vaccine lacks data on very frail older adults and those with weakened immune systems — populations that stand to benefit considerably from improved influenza (搜索) protection. The advisory panel's deliberations will weigh the available efficacy and safety evidence against these remaining data gaps as the agency moves toward a final decision.